Schedule 13G ownership disclosure

Keros Therapeutics Inc

Common Stock, $0.0001 par value per share · CUSIP: 492327101

Event date: 2025-04-30

Filing-level shares
113,803.0
Percent of class
0.2%
  • JPMORGAN CHASE & CO.

    Shares: 113,803.0 · Class: 0.2%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0000019617-25-000437
Form type
SCHEDULE 13G/A
Filer
JPMORGAN CHASE & CO
CIK
CIK 19617
Filed
May 05, 2025
Reporting period
Apr 30, 2025
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub